Briva
Generic Name
Brivaracetam 25 mg tablet
Manufacturer
General Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| briva 25 mg tablet | ৳ 40.00 | ৳ 400.00 |
Description
Overview of the medicine
Briva 25 mg Tablet contains Brivaracetam, an antiepileptic medicine used to treat partial-onset seizures and primary generalized tonic-clonic seizures (adjunctive therapy) in adults and children 4 years of age and older. It works by reducing abnormal activity in the brain.
Uses & Indications
Dosage
Adults
Initial dose 50 mg/day (25 mg twice daily), titrated up to a maintenance dose of 50 mg to 200 mg/day (25 mg to 100 mg twice daily) based on individual response and tolerability.
Elderly
No specific dose adjustment is required based on age alone, but caution should be exercised considering potential comorbidities.
Renal_impairment
No dose adjustment is required for patients with renal impairment, including those on hemodialysis.
How to Take
Take orally, with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew.
Mechanism of Action
Brivaracetam selectively binds with high affinity to synaptic vesicle protein 2A (SV2A) in the brain, thereby inhibiting neurotransmitter release and reducing neuronal excitability, which helps to prevent and control seizures.
Pharmacokinetics
Onset
Relatively rapid, with effects observed shortly after administration.
Excretion
Mainly through renal excretion (95% of dose), with about 65% as metabolites and 35% as unchanged drug.
Half life
Approximately 9 hours.
Absorption
Rapid and complete absorption after oral administration; peak plasma concentrations reached within 0.5 to 2 hours.
Metabolism
Primarily hydrolyzed via non-CYP mediated amide hydrolysis, with a minor contribution from CYP2C19-mediated hydroxylation.
Side Effects
Contraindications
- •Hypersensitivity to Brivaracetam or any of its excipients.
- •Hypersensitivity to other pyrrolidine derivatives.
Drug Interactions
Phenytoin
High doses of Brivaracetam (e.g., 200 mg/day) may increase phenytoin plasma concentrations.
Rifampicin
May decrease plasma concentrations of Brivaracetam due to induction of hepatic enzymes.
Carbamazepine
Concomitant use may increase the plasma concentration of brivaracetam’s active metabolite, which is pharmacologically inactive.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. Symptoms may include somnolence, dizziness, nausea, and ataxia. Management should be symptomatic and supportive, including general supportive measures and monitoring of vital signs.
Pregnancy & Lactation
Pregnancy Category C. Use only if the potential benefit justifies the potential risk to the fetus. It is not recommended during breastfeeding as Brivaracetam is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2-3 years from manufacturing date
Availability
Available in pharmacies and hospitals
Approval Status
FDA Approved (2016) and DGDA Approved
Patent Status
Generic available, original patent expired/approaching expiry in some markets
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
